The Phase I trial involved 10 patients with relapsed or refractory classical Hodgkin lymphoma or CD30 + T-cell lymphoma, yielding highly positive results. Dr. Javier Briones, Head of the ...

Multidisciplinary efforts help promote the success of clinical trials and innovation for patients with various forms of ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

The phase I clinical trial included ten patients with relapsed or refractory classical Hodgkin lymphoma or CD30-positive T-cell lymphoma, with very positive results. According to Dr. Javier Briones, ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

To diagnose non-Hodgkin‘s lymphoma, doctors may use blood tests, biopsies, and imaging scans such as CT scans or MRIs. These tests help doctors confirm the presence of the disease and plan the ...

Promising results in the Phase I clinical trial The Phase I clinical trial involved ten patients with relapsed or refractory classical Hodgkin lymphoma or CD30+ T-cell lymphoma, yielding highly ...